Amgen to acquire privately held KAI Pharmaceuticals
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.
Open-source drug research consortium draws a major new champion
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (Takeda) has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. The SGC is based at the Universities of Toronto, Canada, and Oxford, England.
Roche sends second letter to Illumina shareholders
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche's increased offer and vote for Roche's independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche's increased offer.
Neupro® approved by U.S. FDA for Parkinson's disease and Restless Legs Syndrome
- Details
- Category: UCB
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro® (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
Amgen and AstraZeneca announce collaboration to jointly develop and commercialize clinical-stage inflammation portfolio
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and AstraZeneca Plc, announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).
Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines
- Details
- Category: Novartis
Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature, may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.
More Pharma News ...
- Bayer HealthCare and Beijing's Tsinghua University extend innovative drug discovery partnership
- Sanofi and Regeneron report phase 2 data for potential first-in-class lipid-lowering PCSK9 antibody
- US court denies preliminary injunction application against the FDA and dismisses AstraZeneca's lawsuit
- Roche's Herceptin given by subcutaneous injection offers greater convenience and reduces costs
- UK court finds SEROQUEL XR® formulation patent invalid
- Abbott selects AbbVie as new name for future research-based pharmaceutical company
- Remaining TC-5214 Phase III efficacy studies do not meet endpoint